Effect of heptavalent pneumococcal conjugate vaccination on invasive pneumococcal disease in preterm born infants

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Rückinger, Simon ^a   van der Linden, Mark ^b   von Kries, Rüdiger ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

AGE; ARTICLE; BACTERIAL INFECTION; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFECT; FEMALE; GERMANY; HUMAN; INFECTION CONTROL; INVASIVE PNEUMOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MALE; NEWBORN; PNEUMOCOCCAL INFECTION; PREMATURITY; RISK REDUCTION; VACCINATION; HEALTH SURVEY; IMMUNOLOGY; INCIDENCE; PREVENTIVE HEALTH SERVICE; PROSPECTIVE STUDY;

DISEASE NOTIFICATION; GERMANY; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; INFANT, NEWBORN; INFANT, PREMATURE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES;

EID: 76949109387     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-12     Document Type: Article

References (25)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, Lee E, Mulholland K, Levine OS, Cherian T. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 2009, 374:893-902. 10.1016/S0140-6736(09)61204-6, 19748398.
2. de Bedford H, Louvois J, Halket S, Peckham C, Hurley R, Harvey D. Meningitis in infancy in England and Wales: follow up at age 5 years. Bmj 2001, 323:533-536. 10.1136/bmj.323.7312.533, 48156, 11546697.
3. Davidson M, Schraer CD, Parkinson AJ, Campbell JF, Facklam RR, Wainwright RB, Lanier AP, Heyward WL. Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. Jama 1989, 261:715-718. 10.1001/jama.261.5.715, 2911166.
4. Haddy RI, Perry K, Chacko CE, Helton WB, Bowling MG, Looney SW, Buck GE. Comparison of incidence of invasive Streptococcus pneumoniae disease among children before and after introduction of conjugated pneumococcal vaccine. Pediatr Infect Dis J 2005, 24:320-323. 10.1097/01.inf.0000157090.40719.9b, 15818291.
5. Rendi-Wagner P, Georgopoulos A, Kundi M, Mutz I, Mattauch M, Nowak J, Mikolasek A, Vecsei A, Kollaritsch H. Prospective surveillance of incidence, serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae among hospitalized children in Austria. J Antimicrob Chemother 2004, 53:826-831. 10.1093/jac/dkh211, 15073163.
6. Syriopoulou V, Daikos GL, Soulis K, Michos A, Alexandrou H, Pavlopoulou I, Pagali IPA, Hadjichristodoulou C, Theodoridou M. Epidemiology of invasive childhood pneumococcal infections in Greece. Acta Paediatr Suppl 2000, 89:30-34. 10.1080/080352500300051512, 11194795.
7. Centers for Disease Control and Prevention (CDC) Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep 2005, 54:893-897. Centers for Disease Control and Prevention (CDC).
8. Centers for Disease Control and Prevention (CDC) Invasive Pneumococcal Disease in Children 5 Years After Conjugate Vaccine Introduction --- Eight States, 1998--2005. MMWR Morb Mortal Wkly Rep 2008, 57:144-148. Centers for Disease Control and Prevention (CDC).
9. Black S, France EK, Isaacman D, Bracken L, Lewis E, Hansen J, Fireman B, Austrian R, Graepel J, Gray S, Klein NP. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26:771-777. 10.1097/INF.0b013e318124a494, 17721369.
10. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006, 354:1455-1463. 10.1056/NEJMoa051642, 16598044.
11. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003, 348:1737-1746. 10.1056/NEJMoa022823, 12724479.
12. Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev Vaccines 2009, 8:1351-1364. 10.1586/erv.09.78, 19803758.
13. Rückinger S, Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 2009, 27:4136-4141. 10.1016/j.vaccine.2009.04.057, 19406190.
14. Hjuler T, Wohlfahrt J, Simonsen J, Kaltoft MS, Koch A, Kamper-Jorgensen M, Biggar RJ, Melbye M. Perinatal and crowding-related risk factors for invasive pneumococcal disease in infants and young children: a population-based case-control study. Clin Infect Dis 2007, 44:1051-1056. 10.1086/512814, 17366448.
15. Langkamp DL, Hoshaw-Woodard S, Boye ME, Lemeshow S. Delays in receipt of immunizations in low-birth-weight children: a nationally representative sample. Arch Pediatr Adolesc Med 2001, 155:167-172.
16. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, Elvin L, Ensor KM, Hackell J, Siber G, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19:187-195. 10.1097/00006454-200003000-00003, 10749457.
17. Shinefield H, Black S, Ray P, Fireman B, Schwalbe J, Lewis E. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002, 21:182-186. 10.1097/00006454-200203000-00003, 12005078.
18. Esposito S, Pugni L, Bosis S, Proto A, Cesati L, Bianchi C, Cimino C, Mosca F, Principi N. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants. Vaccine 2005, 23:1703-1708. 10.1016/j.vaccine.2004.09.029, 15705475.
19. Ruggeberg JU, Collins C, Clarke P, Johnson N, Sinha R, Everest N, Chang J, Stanford E, Balmer P, Borrow R, et al. Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine 2007, 25:264-271. 10.1016/j.vaccine.2006.07.036, 17070968.
20. D'Angio CT. Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability. Paediatr Drugs 2007, 9:17-32. 10.2165/00148581-200709010-00003, 17291134.
21. Von Kries R, Heinrich B, Hermann M. Pädiatrische Epidemiologie in Deutschland: Forschungsinstrument ESPED (Erhebungseinheit für seltene pädiatrische Erkrankungen in Deutschland). Monatsschrift Kinderheilkunde 2001, 149:1191-1197.
22. von Kries R, Siedler A, Schmitt HJ, Reinert RR. Proportion of invasive pneumococcal infections in German children preventable by pneumococcal conjugate vaccines. Clin Infect Dis 2000, 31:482-487. 10.1086/313984, 10987709.
23. Grenier D, Elliott EJ, Zurynski Y, Rodrigues Pereira R, Preece M, Lynn R, von Kries R, Zimmermann H, Dickson NP, Virella D. Beyond counting cases: public health impacts of national Paediatric Surveillance Units. Arch Dis Child 2007, 92:527-533. 10.1136/adc.2006.097451, 17158859.
24. Neufeld F. über die Agglutination der Pneumokokken und über die Theorie der Agglutination. Zeitschrift für Hygiene und Infektionskrankheiten 1902, 40:54-72.
25. American Academy of Pediatrics Immunization in special clinical circumstances. Red Book: Report of the Committee on Infectious Diseases 1997, 48. IL: American Academy of Pediatrics, Peter G, Elk Grove Village, IL, 24, American Academy of Pediatrics.